ResMed buys HME software vendor Jaysec


Wednesday, 11 February, 2015

ResMed (ASX:RMD) has announced the acquisition of Jaysec, a US-based provider of internet-based software for the home medical equipment (HME) industry.

Jaysec provides products to help HME providers resupply their patients and communicate with referring clinicians.

The company’s GoJaysec automated resupply offering uses interactive, voice, text and email communications to allow customers to authorise HME resupplies for equipment including CPAP masks and accessories - ResMed’s bread and butter.

ResMed has revealed plans to incorporate Jaysec software into its product line.

“Acquiring Jaysec furthers our commitment to helping HMEs drive business efficiencies while delivering positive patient outcomes. We’re excited to bring Jaysec into the ResMed fold, and we look forward to supporting existing and new customers alike,” ResMed President of Global Healthcare Informatics Raj Sodhi said.

ResMed separately revealed that it has entered an agreement to incorporate its AirView patient management system with Brightree’s HME billing and business management software.

ResMed and Brightree have been collaborating since 2013 to improve workflow efficiency, ease of use and business benefits for their joint customers.

“Directly integrating AirView into the industry-leading Brightree software platform underscores ResMed’s commitment to providing our HME customers with the tools they need, in the formats of their choosing, to help drive business efficiencies and optimal care,” Sodhi said.

ResMed (ASX:RMD) shares were trading 1.108% higher at $0.09 as of around 2 pm on Wednesday.

Related News

High-potency cannabis use leaves a unique mark on DNA

Frequent users of high-potency cannabis have changes in genes related to mitochondrial and immune...

Scaffold-based method for culturing antitumour bacteria

Bacteria-based cancer therapy represents an exciting new treatment option — but in order to...

mpox vaccine appears safe and effective in adolescents

Interim analysis of an mpox vaccine trial has found the vaccine is safe in adolescents and...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd